Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Based on positive results in laboratory animals, chlorpromazine was given a clinical trial in humans to determine if it could reduce fluid losses during cholera. In animals, the chlorpromazine inhibited cholera toxin-stimulated intestinal adenylate cyclase and fluid secretion. Therefore, 11 cholera patients suffering severe diarrhea (360-1340 ml/hour) and vomiting were given either intramuscular chlorpromazine (1 mg/kg or 4 mg/kg) (n=8) or oral chlorpromazine of the same dose (1 mg/kg) (n=3). Overall reduction in stool output of 66% in the treated patients was evident after 32 hours of treatment. The decrease in treated patients was significantly greater than the reduction in nontreated patients (26%) during the same 32-hour course of illness. Patients' comfort was also enhanced by the decrease in nausea and mild sedative qualities of chlorpromazine, and no hypotension was observed in these well-hydrated patients.
 ...
PMID:Chlorpromazine reduces fluid-loss in cholera. 8 63

In Britain more mothers want to breastfeed their infants. For medical staff who have been trained in a traditional of bottle feeding the problem of failure to thrive because of inadequate breastfeeding may be less well recognized than formerly. There appears to be 2 main types of clinical presentation: fretful underfed infants and "contented" underfed infants. With the fretful underfed infants there is often a history of constant crying and irritability associated with frequent but short feeds. Colic and vomiting are common and the infants look undernourished and show poor weight gain. The "contented" underfed infants give the impression of being satisfied after feedings, but they look undernourished and do not show adequate weight gain. The extent to which inadequate breastfeeding contributes to the problem of failure to thrive in Britain is unknown. Among a group of 21 infants under the age of 6 months who were admitted to the hospital during the January 1 to December 31, 1978 period, failure of breastfeeding was diagnosed in 9 babies. In antenatal classes the practical aspects of breastfeeding should be discussed, particularly with primigravidas. There needs to be emphasis on the management of breastfeeding. The importance of frequent feeding in establishing lactation should be stressed. Hospitals have an important role in getting breastfeeding off to a good start, and community health workers need to become aware that breastfeeding does not exempt babies from being underfed. Underfeeding at the breast must be recognized as a likely diagnosis in breast-fed infants who are failing to thrive. For the contented underfed baby it is sometimes worthwhile trying to increase the frequency of breastfeeding. For the fretful underfed infant possible reasons for poor milk production must be considered.
 ...
PMID:Is inadequate breast-feeding an important cause of failure to thrive? 8 17

A peripheral dopaminergic blocking agent, domperidone (60 mg daily), or placebo was given, double-blind, to 17 parkinsonian patients who also received increasing doses of bromocriptine. Combined treatment with domperidone reduced total disability by 76% in 8 patients receiving a mean dose of 148 mg of bromocriptine daily. There was no vomiting and involuntary movements and psychic disturbances were similar to those in patients on levodopa and a peripheral decarboxylase inhibitor. In 9 patients taking placebo instead of domperidone, the average daily dose of bromocriptine could not be raised beyond 92 mg. The mean total disability score in this group was reduced by only 48%. Thus, peripheral blockade of dopamine receptors is a promising means of limiting the adverse side-effects of the treatment of parkinsonism with central dopaminergic receptor stimulating agents such as bromocriptine.
 ...
PMID:Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. 8 62

In December, 1976, an outbreak of gastroenteritis occurred at a resort camp in Colorado. Data obtained by questionnaire from 760 persons indicated that 418 (55%) had had gastroenteritis at the camp or within a week of leaving it, with peak onset within a two-day period. Symptoms included vomiting (81%), diarrhoea (65%), and fever (49%); median duration of illness was twenty-four hours. The attack-rate increased with consumption of water or ice-containing beverages. The camp water supply was found to be inadequately chlorinated and contaminated by a leaking septic tank. Although routine laboratory tests did not reveal bacterial, viral, or parasitic pathogens, immune electron microscopy detected virus-like particles in two of five diarrhoeal stool filtrates. Oral administration of one of these bacteria-free filtrates to two volunteers induced a gastrointestinal illness similar to that observed in the camp visitors.
 ...
PMID:A waterborne outbreak of gastroenteritis with secondary person-to-person spread. Association with a viral agent. 8 27

Forty patients with advanced head and neck cancer were treated with combined Cis-platinum-Bleomycin chemotherapy. Cis-diammine dichloroplatinum (DDP) 120 mg/m2 iv was given after prehydration, with mannitol diuresis on Day 1. On Day 3, an initial loading dose of Bleomycin 15 mg/m2 was given by rapid iv push followed by continuous 24 hour intravenous infusion of Bleomycin 15 mg/m2 Day 3 through Day 10. DDP 120 mg/m2 iv was administered again on Day 22. The patients were evaluated for tumor response and resectability between Day 29 to Day 35. Of 39 patients who were evaluable, there were 8 complete responses or CR (20%) and 22 partial responses or PR (56%), for a major response rate of 76%. Nineteen patients had surgery (14 patients whose lesions were initially inoperable and 5 patients who were initially operable). Chemotherapy toxicity in 40 patients included alopecia (40), vomiting (39), mucositis (11), skin rash (10), fever (17), weight loss of more than 5 lbs. (25), WBC less than 3,000 (2), platelets less than 100,000 (1), peak serum creatinine of 2 mg% (3), severe-hearing loss (1), hypersensitivity reaction (2). Surgical complication in 19 patients were pharyngocutaneous fistulae (2), wound dehiscence (1), meningitis and brain abscess (1). There was one death secondary to nephrotoxicity. This particular combination chemotherapy when given as initial treatment, appears very effective in reduction of tumor bulk. Long-term follow-up and randomization is necessary to determine effect upon survival.
 ...
PMID:Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion. 8 55

The effects of the intravenous or intracerebroventricular injection of the stereoisomers, and the racemic mixture, of allylglycine (2-amino-pent-4-enoic acid) have been studied in baboons, Papio papio, with photosensitive epilepsy. Enhancement of the natural syndrome of photosensitivy epilepsy is seen 1-12 h (maximally at 3-8 h) after L-allyglycine, 100 mg/kg, intravenously, or D,L-allyglycine, 200 mg/kg, intravenously. Such enhancement is seen with a slower onset, and to a lesser, and more variable, extent after D-allyglycine, 500-750 mg/kg, intravenously. Brief focal or generalised seizures occurred (in the absence of intermittent photic stimulation) after L-allyglycine, 150-200 mg/kg, intravenously. This effect is similar to that previously observed after D,L-allyglycine, 300-400 mg/kg. D-Allyglycine, 780 mg/kg, intravenously produced episodes of vertical nystagmus with increased extensor motor tone, but no 'spontaneous' seizures. Intracerebroventricular injection of L-allylglycine, D-allyglycine or D,L-allyglycine, 100 mg in 1 ml saline, did not modify the natural syndrome of photosensitive epilepsy. D-Allylglycine, or D,L-allyglycine, 100 mg intracerebroventricularly, after 1-2 h gave rise to a syndrome with vomiting, sustained vertical nystagmus, and intermittent extensor spasms. The results are interpreted in terms of regional differences in the metabolism of the two isomers to active compounds that can inhibit glutamic acid decarboxylase. D-Allylglycine is active only at the brain stem and cerebellum because D-amino acid oxidase is largely confined to these brain areas.
 ...
PMID:Proconvulsant, convulsant and other actions of the D- and L-stereoisomers of allylglycine in the photosensitive baboon, Papio papio. 8 42

Elective esophagogastrectomy and reconstruction by esophagogastrostomy were performed on 55 patients with malignant tumors of the midesophagus, despite invasion of contiguous structures in 60% and regional lymph node involvement in 75%. The operations were invariably palliative. Two patients died within thirty days of operation. Dysphagia was relieved and oral alimentation resumed in the other 53. Twenty-nine patients who had experienced painful swallowing and 16 who had vomiting obtained relief. Survival curves show no improvement from previous decades for patients with malignancies of the middle third of the esophagus. The mean survival was 10.4 months. Mean survival of patients with liver metastases was 3.5 months.
 ...
PMID:Esophagogastrectomy for carcinoma of the middle third of the esophagus. 9 20

Thirty-seven children and adolescents with acute leukemia in relapse were treated with cyclocytidine in a cooperative group setting. Only one of the 27 evaluable patients achieved complete remission. A significant decrease (greater than or equal to 20%) in circulating and/or bone marrow leukemia cells occurred in an additional five patients. Drug toxicity was evaluated in 35 patients and included ten cases of jaw pain, two cases of hypotension, one case of fever, and one case of severe vomiting.
 ...
PMID:Cyclocytidine in the treatment of refractory acute childhood leukemia: a Southwest Oncology Group Phase I-II study. 9 13

One hundred eighteen patients with metastatic carcinoid tumor were randomized to treatment with streptozotocin combined with cyclophosphamide or with 5-fluorouracil (5-FU). Commonly experienced side effects were nausea, vomiting, leukopenia, thrombocytopenia, and nephrotoxicity. Objective response rates among eligible and evaluable patients treated with the 5-FU combination was 14 of 42 (33%) and with the cyclophosphamide combination, 12 of 47 (26%). Among those patients with carcinoids primary to the small bowel the respective response rates were 44% and 37%. The overall response rates for patients with carcinoids of pulmonary or unknown origin were only 12% and 17%. There was no significant difference in patient survival between the two treatment arms. Among 11 patients who received crossover therapy with 5-FU alone there were two responders. There were no responders among eight patients treated with cyclophosphamide alone. Urinary 5HIAA excretion proved to be a useful biologic marker in these patients that correlated well with the observed measurements of tumor bulk. Median survival times from the diagnosis of unresectable malignant disease related to sites of origin of carcinoid tumor were the following: small bowel, 28.4 months; pancreas, 24.0 months; lung, 15.1 months; and unknown origin, 9.0 months. Metastatic carcinoid tumor is a malignant disease susceptible to chemotherapeutic approaches and continued investigation of the therapy of these neoplasms should be strongly encouraged.
 ...
PMID:Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. 9 82

A fecal filtrate of human origin containing the Norwalk agent of epidemic viral gastroenteritis was administered by stomach tube to chimpanzees in an attempt to induce diarrheal disease. Significant postchallenge serum antibody rises against Norwalk viral antigens were demonstrated in all animals using the techniques of immune electron microscopy and radioimmunoassay. In addition, viral antigens were detected in feces from five of nine animals using radioimmunoassay. Clinical illness characterized by diarrhea and/or vomiting did not occur. Infection was transmitted subsequently by feeding four additional chimpanzees a fecal filtrate prepared from one of the previously infected animals. Development of an antibody response in four animals and detection of viral antigen in two animals that received this passage filtrate indicated that viral replication had occurred in the absence of clinical illness. The availability of the chimpanzee as an experimental animal host susceptible to infection with the Norwalk agent should facilitate the study of epidemic viral gastroenteritis.
 ...
PMID:Experimental infection of chimpanzees with the Norwalk agent of epidemic viral gastroenteritis. 9 64


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>